InvestorsHub Logo
Followers 5
Posts 542
Boards Moderated 0
Alias Born 07/23/2012

Re: 1syndicate post# 2226

Tuesday, 01/10/2017 4:58:34 PM

Tuesday, January 10, 2017 4:58:34 PM

Post# of 3707
I think what spooked everyone yesterday was the PR from AMAD about the timeline; in a conference call on 15 Nov. Carl Spana said they were looking at filing the bremelanotide NDA in the second half of calendar 2017. AMAD in a PR stated the following

"The anticipated filing date in the U.S. for a new drug application (NDA) for Rekynda is in early 2018, with an anticipated approval and launch by early 2019."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PTN News